Related by context. All words. (Click for frequent words.) 65 landmark ATHENA 64 multicenter placebo controlled 62 placebo controlled randomized 60 placebo controlled Phase III 59 number NCT# ClinicalTrials.gov 59 multicenter randomized placebo controlled 59 intravenous RSD# 59 Phase III randomized 58 evaluating mipomersen 58 AVOREN 58 TEAEs 58 RE LY ® 58 ExTRACT TIMI 58 multicenter randomized double 58 Wisconsin Sleep Cohort 58 placebo controlled clinical 58 prospectively defined 58 CARE HF 58 multicenter Phase III 58 blind randomized multicenter 58 primary hypercholesterolemia 58 Carotid Revascularization Endarterectomy vs. 58 GetGoal Phase III 58 subgroup analyzes 57 PCI ExTRACT TIMI 57 Val HeFT 57 active comparator 57 liver transplant recipients 57 BR.# 57 azilsartan medoxomil 57 RIO Diabetes 57 multicentre randomized double 57 trials RCTs 57 VADT 57 ARCOXIA 57 ATACAND 57 multicenter multinational 57 lenalidomide Revlimid R 57 PLX STROKE targeting 57 BRIM3 56 PRIMO CABG 56 prospective randomized placebo 56 MGd 56 ENDEAVOR II 56 CALGB # [002] 56 GRNCM1 56 cardiovascular hospitalizations 56 Group B CALGB 56 Primary endpoints 56 retinal thrombosis hemorrhages 56 prospective observational 56 malignant mesothelioma Alfacell 56 dosing cohort 56 Clinical Antipsychotic Trials 56 IMPROVE HF 56 retrospective observational study 56 relapsed MM 56 nonfatal MI 56 placebo controlled trials 56 nonfatal myocardial infarctions 56 MERLIN TIMI 56 thyrotropin levels 56 EDEMA3 56 non valvular atrial 56 Randomized Double blind 56 Sorafenib HCC Assessment 56 Meta analyzes 56 EDEMA3 trial 56 diastolic blood pressures 55 CHAMPION PCI 55 randomized Phase III 55 CVD mortality 55 blind multicenter 55 blind randomized controlled 55 receiving concomitant corticosteroids 55 basal bolus regimen 55 randomized multicenter 55 PLCO 55 FOLFOX6 chemotherapy regimen 55 irbesartan 55 novel VDA molecule 55 CYPHER R stent 55 retinal vein occlusion induced 55 Folfox 55 antidepressants fluoxetine 55 asthma immunotherapeutic 55 TRITON TIMI 55 Phase IIb randomized 55 SYMMETRY trial 55 prospective multicenter 55 RECORD1 55 multinational multicenter randomized 55 RoACTEMRA 55 NO# [002] 55 viral kinetic 55 meta regression 55 EMPHASIS HF trial 55 glycosylated hemoglobin HbA1c 55 double blinded placebo 55 observer blinded randomized 55 VICTOR E1 55 NCT# ClinicalTrials.gov 55 rash pruritus nausea 55 AIR2 Trial 55 recombinant PSMA vaccine 55 unresectable HCC 55 placebo controlled clinical trials 55 HCV SPRINT 55 myocardial infarction stroke 55 AVERROES 55 LibiGel Phase III 55 prospective multicenter randomized 55 HCV RESPOND 2 55 postoperative mortality 55 ANCHOR trial 55 Combination REOLYSIN R 55 deCODE AF TM 55 Serious adverse reactions 55 MEND CABG 55 multicenter randomized 55 Stenting Trial CREST 55 DASISION 55 hyperphenylalaninemia HPA due 55 COU AA 55 ORAL Sync 55 Coronary artery calcification 55 SPIRIT FIRST 54 DIRECT Trial 54 placebo controlled studies 54 prospective randomized multicenter 54 By JENNIFER LEARN 54 controlled multicenter 54 CAMMS# 54 BRIM2 54 albiglutide 54 Prostate Lung Colorectal 54 riociguat 54 Alpha Tocopherol Beta Carotene 54 HMG CoA reductase inhibitors 54 Randomized Placebo Controlled 54 cancer indications bafetinib 54 CATIE AD 54 myocardial infarction ventricular fibrillation 54 EURIDIS 54 Vidaza ® 54 masked placebo controlled 54 Randomized Phase II 54 IMPACT DCM 54 MADIT II 54 multicentre prospective 54 gadobutrol 54 EchoCRT 54 ROCKET AF 54 Cochrane Systematic Review 54 myocardial infarctions MIs 54 asymptomatic carotid stenosis 54 placebo controlled Phase 54 blind placebo 54 INTERHEART study 54 randomized multicentre 54 nonfasting triglyceride levels 54 double blinded randomized 54 nondiabetic patients 54 galiximab 54 multicenter Phase II 54 evaluating tivozanib 54 PREZISTA r 54 multicenter randomized clinical 54 undergone radical prostatectomy 54 multicentre study 54 serum lipid levels 54 patients undergoing percutaneous 54 pharmacokinetic PK 54 placebo controlled dose escalation 54 Acute Ischemic Stroke 54 SORT OUT III 54 CYT# potent vascular disrupting 54 anthracycline taxane 54 CRESTOR #mg 54 nonfatal stroke 54 CHD CVD 54 unfractionated heparin UFH 54 CIMZIA TM certolizumab pegol 54 ENDEAVOR III 54 randomized controlled multicenter 54 multicentre 54 EXPLORE Xa 54 ABSORB trial 54 Phase IIIb 54 angioplasties stents 54 myocardial infarctions 54 preserved ejection fraction 53 Tovaxin Phase IIb 53 NSABP C 53 REVIVE TA 53 prospective multicentre 53 NHANES III 53 HORIZONS AMI trial 53 receiving INTRON 53 pain palliation 53 dysglycemia 53 secondary efficacy endpoints 53 pharmacodynamic profiles 53 sorafenib tablets 53 NCT# 53 NATRECOR ® 53 phase IIb study 53 PMX # heptagonist 53 paclitaxel eluting stents 53 Raloxifene Evaluation MORE 53 comparing XIENCE V 53 oral rivaroxaban 53 ASCEND HF 53 HCV NS5B polymerase 53 ENL recurrence 53 composite endpoint 53 metaglidasen 53 carotid atherosclerosis 53 TMC# C# 53 ECASS 53 Prostate Cancer Prevention 53 RIO Lipids 53 clozapine Clozaril 53 fasting glucose levels 53 PEGINTRON TM 53 oral FTY# 53 Subgroup analysis 53 oxycodone CR 53 multicenter prospective 53 onset diabetes mellitus 53 ritonavir boosted 53 reinfarction 53 dose regimens 53 fallopian tube cancers 53 dose dose escalation 53 candesartan cilexetil 53 Phase Ib II 53 colesevelam HCl 53 multicenter randomized controlled 53 bepotastine besilate nasal spray 53 confirmatory clinical 53 elevated serum creatinine 53 nonrandomized 53 PRIMO CABG2 53 Naive Patients 53 TG MV 53 cardiac myosin activator omecamtiv 53 Cholesterol Levels SPARCL 53 underwent CABG 53 valsartan amlodipine 53 blinded randomized placebo controlled 53 ONTARGET 53 NOXAFIL Oral Suspension 53 XL# XL# XL# 53 adjunctive placebo 53 Xelox 53 coronary revascularization 53 randomized controlled clinical trials 53 phase IIb clinical 53 posaconazole 53 PLCO trial 53 PROactive study 53 STRIDE PD 53 LymphoStat B belimumab 53 specific antigen PSA 53 evaluating Xcytrin 53 symptomatic BPH 53 REALITY Trial 53 Elevated triglycerides 53 UKPDS 53 baseline HbA1c 53 TAXUS VI 53 definite stent thrombosis 53 sNDA submission 53 NATRECOR R 53 Myocardial Infarction Study 53 vaccinated PNH patients 53 bone marrow reticulin deposition 53 CAPACITY trials 53 tertile 53 onset atrial fibrillation 53 colorectal cancer incidence 53 Vidaza R 53 torcetrapib atorvastatin 53 ToGA 52 forodesine 52 Phase 2b randomized 52 MELD scores 52 severe dermatologic toxicities 52 CALGB 52 blind randomized placebo 52 colorectal adenoma 52 rosuvastatin Crestor 52 later Ettore Campogalliani 52 pharmacogenomic translational research 52 serum uric acid 52 heFH 52 IIIa inhibitor 52 elotuzumab 52 HeFT 52 cilostazol 52 Tekamlo 52 Phase 1b clinical trials 52 FAME Study 52 arterial thromboembolic events 52 bazedoxifene conjugated estrogens 52 metformin sulfonylurea 52 headache nasopharyngitis 52 randomized controlled clinical 52 del 5q MDS 52 metastatic HRPC 52 ascending dose 52 dosing cohorts 52 oral deforolimus 52 Epidemiologic studies 52 retrospective cohort 52 Zoraxel 52 CLARITY TIMI 52 cisplatin gemcitabine 52 systemic embolism 52 Telik logo TELINTRA 52 TQT studies 52 thorough QT 52 Screening Trial DMIST 52 including eniluracil ADH 52 aldosterone antagonist 52 Hypertensive adverse reactions 52 GEM OS2 52 Prostate AdenoCarcinoma Treatment 52 Deforolimus 52 DAPT Study 52 cerebrovascular diseases 52 NSABP B 52 Phase #/#a 52 relapsed myeloma 52 Randomized Double Blind 52 randomized controlled trials RCTs 52 Homocysteine levels 52 randomized placebo controlled 52 CLL8 52 Multicenter Automatic Defibrillator Implantation 52 OPT CHF 52 multicenter study 52 catheter occlusion 52 ongoing Phase 1b 52 AEG# 52 PROPEL trial 52 myocardial infarction MI 52 ORAL Solo 52 congenital malformations 52 blinded placebo controlled 52 ConclusionThis 52 ALN VSP Phase 52 dosage regimens 52 alvespimycin 52 venlafaxine XR 52 salmeterol inhalation powder 52 prospective randomized 52 AVN# Phase 52 vitamin B# folic acid 52 Bayer HealthCare Onyx Pharmaceuticals 52 rALLy 52 dirucotide MBP# 52 bacterial contamination outbreaks 52 Left Ventricular Dysfunction 52 tenofovir emtricitabine 52 epidemiologic studies 52 RSD# oral 52 Digital Mammographic Imaging 52 R sorafenib tablets 52 Randomized Evaluation 52 BOLDER II 52 multicenter clinical 52 HER2 expression 52 Ophena TM 52 Matrox Bring 52 ADVANCE PD 52 XIENCE V demonstrated 52 deferiprone 52 placebo controlled 52 coxib 52 #F FDG PET 52 solid tumors ZYBRESTAT 52 Phase IIIb clinical 52 Study ARIC 52 angiotensin analog 52 ID NCT# 52 EQUIP OB 52 Entereg R 52 AIR CF1 52 SPIRIT IV 52 dose cohorts 52 Betaferon ® 52 naïve HCV 52 Androxal TM 52 pioglitazone HCl 52 placebo controlled multicenter 52 Phase #b/#a clinical 52 CHD mortality 52 fluvastatin 52 BCIRG 52 randomized controlled 52 phase III ACCLAIM 52 rheumatoid arthritis psoriatic arthritis 52 e HEALING 52 Board DSMB 52 elevated fasting glucose 52 observational cohort 52 Phase III VISTA 52 echocardiographic parameters 52 label multicenter randomized 52 recurrent malignant glioma 52 Randomized Phase 51 Proellex TM 51 CEL SCI Phase III 51 zoledronic acid Reclast 51 events SAEs 51 GAMMAGARD 51 hsCRP levels 51 HBeAg negative 51 prednisone prednisolone plus 51 infliximab monotherapy 51 RE LY 51 tolvaptan 51 trastuzumab emtansine T DM1 51 APTIVUS 51 serum estradiol 51 Swedish Mammography Cohort 51 HGS ETR1 mapatumumab 51 controlled dose escalation 51 anti arrhythmic 51 Placebo Controlled 51 RBC folate 51 EOquin TM 51 Muscular colt 51 dose escalation Phase 51 Bracketed figures 51 MADIT CRT trial 51 serum GGT 51 Edge STudy 51 SYNTAX trial 51 BARI 2D 51 controlled multicenter Phase 51 modified REGENESIS Phase IIb 51 undergoing elective percutaneous 51 recurrent metastatic ovarian cancer 51 INSPIRE Trial Phase III 51 Phase III ADT 51 serum creatinine levels 51 multicenter clinical trials 51 TAXUS ATLAS 51 randomized double 51 prospective observational studies 51 European Sepsis Trial 51 creatinine levels 51 evaluating T DM1 51 R# #mg BID 51 ST Segment Elevation 51 PreCISe 51 Multicenter AIDS 51 TAXUS p value 51 LUX Lung 51 MEK Inhibitor 51 microalbumin test 51 CombAT 51 ThermoDox R 51 Pivotal Trial 51 protease inhibitor PI 51 ACS Molecular Pharmaceutics 51 Multaq R 51 mGluR5 NAM 51 TAXUS IV 51 aleglitazar 51 VIRAMUNE XR 51 registrational Phase 51 Platelet Inhibition 51 observational studies 51 melphalan prednisone 51 recurrent glioblastoma multiforme 51 sorafenib Nexavar ® 51 HbA1c levels 51 kidney urologic 51 insulin detemir 51 Rheos System 51 tumor xenograft models 51 discontinuations due 51 worsening thrombocytopenia 51 hydroxyvitamin D levels 51 serum folate 51 lintuzumab SGN 51 SPIRIT III 51 statistically significant correlations 51 ACCORD Lipid 51 Dapagliflozin 51 MAGE A3 ASCI 51 Phase IIIb study 51 glycoprotein IIb IIIa inhibitor 51 TTF Therapy 51 Phase Ib clinical 51 Clinical Outcomes Utilizing Revascularization 51 ENDEAVOR IV 51 Novel Oral 51 SUBSIDIARIES OPERATING STATISTICS 51 Placebo controlled 51 Subgroup analyzes 51 CANCIDAS 51 HbA1C levels 51 Phase Ib IIa 51 Teriflunomide 51 phase IIb trial 51 vaginal progesterone gel 51 Alagebrium 51 aspirin clopidogrel 51 boosted protease inhibitor 51 Pivotal Phase III 51 blind randomized 51 baseline serum creatinine 51 APTIVUS r 51 hole ESI# 51 Exelixis compounds 51 colonoscopy detects precancerous polyps 51 Phase IIb III 51 demonstrated antitumor activity 51 atypical ductal hyperplasia 51 rFVIIa 51 TRANSFORMS 51 followers Patricia Krenwinkle 51 periprocedural MI 51 EOquin TM phase 51 Rosuvastatin 51 multicentre randomized 51 nonvertebral fractures 51 PSADT 51 stent DES 51 PARTNER Trial 51 oral ridaforolimus 51 Diabetic Macular Edema 51 Towering scholar 51 docetaxel Taxotere ® 51 NYHA Class II 51 dose escalation trial 51 plus prednisone 51 coinfection 50 Motesanib 50 unmeasured confounders 50 inhospital 50 Completes Patient Enrollment 50 relapsing remitting MS RRMS 50 trial evaluating PRX# 50 plasma selenium 50 myelofibrosis polycythemia vera 50 phase Ib 50 sulfonylurea glimepiride 50 Dabigatran etexilate 50 HGS# 50 fostamatinib 50 Randomized Study 50 TAXUS V 50 deforolimus 50 de novo kidney transplant 50 Randomized Controlled 50 testing huN# DM1 50 XL# anticancer compounds 50 Thrombolysis 50 INCB# [001] 50 nucleoside naive 50 hemoglobin A1c levels 50 mg administered orally 50 CYPHER R Sirolimus eluting 50 Ribavirin causes 50 Intervention Trial GAIT 50 XL# SAR# 50 NLSY 50 Allovectin 7 ® 50 multicenter 50 COR Diabetes 50 Prospective Randomized 50 opioid induced bowel dysfunction 50 desvenlafaxine succinate 50 Completes Enrollment 50 receiving VELCADE 50 rt PA 50 candidate CRLX# 50 CYPHER ® Sirolimus eluting 50 ABSORB clinical 50 hemoglobin A1c HbA1c 50 univariate analyzes 50 humanized interleukin 6 50 coronary revascularizations 50 multicentre randomized controlled 50 ACTEMRA TM 50 primary generalized tonic 50 Rigel R# 50 prospective randomized controlled 50 evaluating Actimmune 50 impaired glucose metabolism 50 DU #b 50 PRE SURGE 50 interferon gamma 1b 50 REMINYL ® 50 HBeAg negative patients 50 budesonide foam 50 Hb A1C 50 docetaxel chemotherapy 50 locoregional recurrence 50 Baseline characteristics 50 memantine HCl 50 angiotensin receptor blocker ARB 50 #mmHg [001] 50 virus HCV protease inhibitor 50 REVIVE Diabetes 50 Ranolazine 50 MIVI III 50 postmenopausal hormone 50 Multicenter 50 Randomized Clinical Trial 50 Phase III placebo controlled 50 Phase III multicenter 50 Mylotarg 50 mL/min/#.# m 2 50 SUCCEED trial 50 subclinical hyperthyroidism 50 ARIXTRA 50 cTnT levels 50 mg RDEA# 50 DDP# 50 Budesonide foam crofelemer 50 Intervention Effectiveness 50 highest tertile 50 COMFORT II 50 Subgroup Analysis 50 Mg Usa 50 tribulations Groenveld 50 renal dysfunction 50 Trandolapril 50 Empatic ™ 50 meta analyzes 50 somnolence dizziness 50 ACCORD ADVANCE 50 Tolvaptan 50 SYNERGY Stent 50 CLARITY study 50 Secondary endpoints 50 cardiovascular mortality 50 EVEREST II 50 CARDIA study 50 prasterone 50 choline intake 50 perinatal mortality 50 ENESTnd 50 systolic dysfunction 50 severe hypersensitivity reactions 50 SPARCL 50 orally administered inhibitor 50 ORACLE MS 50 rosuvastatin 50 quetiapine risperidone 50 multivariate analyzes 50 nonfasting triglycerides 50 mapatumumab 50 Ovarian Cancer Screening 50 paroxetine Paxil 50 ziprasidone Geodon 50 trastuzumab Herceptin ® 50 bicifadine 50 teriflunomide 50 TBC# 50 pCR 50 left ventricular hypertrophy 50 randomized discontinuation trial 50 metreleptin 50 neuroimaging studies 50 PERSEUS 50 iPrEx study 50 Phase III metastatic melanoma 50 International Verapamil SR 50 resuscitated cardiac arrest 50 Edwards SAPIEN valve 50 Aggressive Reduction 50 ataluren 50 Oral Fingolimod 50 meta analysis pooling 50 clinical pharmacology studies 50 edoxaban 50 estramustine 50 observational cohort study 50 Contrave# 50 MKC# MT 50 randomized multicenter trial 50 Enzastaurin 50 stage IIIb IV 50 neuropsychiatric symptoms 50 antiretroviral naïve 50 NSABP 50 budesonide pMDI 50 aplindore 50 BEXXAR Therapeutic Regimen 50 YONDELIS 50 Neulasta R 50 Paxil paroxetine 50 Hylenski worked 50 Amirhossein Sairafi 50 macrovascular disease 50 pegylated interferons 50 specified primary endpoint 50 multiple logistic regression 50 ENDEAVOR IV clinical 50 unstable angina UA 50 APPRAISE 50 safinamide 50 retrospective cohort study 50 Safinamide 50 gemcitabine Gemzar 50 ribavirin Copegus 50 perampanel 50 PSN# [002] 50 chemotherapy gemcitabine 50 Cardiac Allograft Rejection 50 prognostic variables 50 hypogonadal men 50 diarrhea vomiting nausea 50 Severe hypersensitivity reactions 50 vapreotide acetate 50 CYP#A# CYP#D# 50 R#/MEM # 50 Abb Ltd ABB 50 subtrochanteric 50 pharmacokinetics PK 50 Testosterone MDTS ® 50 dexamethasone Decadron 50 GERD migraine headaches 50 NYHA Class III 50 ALN HPN 50 Selzentry Celsentri 50 multicenter trials 50 bevirimat Study 49 Odyssey HealthCare NASDAQ ODSY 49 bone density measurements 49 elevated triglycerides 49 Nutrition EPIC 49 telomere lengths 49 SEER registry 49 JANUVIA 49 eprotirome 49 AVADO 49 #/#/# Cytokinetics Incorporated 49 triglyceride concentration 49 unique alkylating agent 49 6R BH4 49 Significant mineralized intercepts 49 PORxin TM platforms 49 venous thromboembolisms 49 Fasting blood glucose 49 RRMS patients 49 APTIVUS ritonavir 49 AIM HIGH 49 inhalations twice 49 prospective multicenter study 49 elevated LDL cholesterol 49 FOLFIRI 49 WBRT alone 49 Sapacitabine 49 adjunctive ABILIFY 49 systemic Phase 1b 49 evaluating REVLIMID 49 trastuzumab Herceptin R 49 Afatinib 49 registrational trial 49 tramiprosate Alzhemed TM 49 PROSTVAC TM 49 Dose escalation 49 LHRH antagonists 49 randomized Phase IIb 49 advanced adenomas 49 ASTEROID 49 EDEMA4 49 de aths 49 phase III isavuconazole 49 Phase IIa trials 49 pharmacokinetic characteristics 49 isolated hypertriglyceridemia 49 chlamydia infections 49 Trastuzumab DM1 49 maximally tolerated dose 49 azathioprine monotherapy 49 PM#.# exposure 49 HF ACTION 49 SUTENT ® 49 Controlled Trial 49 symptomatic intracerebral hemorrhage 49 postmenopausal hormone therapy 49 phase IIIb 49 DSMB 49 ascending doses 49 Framingham Offspring Study 49 ocular hypertension 49 Kaplan Meier analysis 49 defibrillator CRT D 49 randomized blinded placebo 49 Efficacy Results 49 histologic subtype 49 elevated LDH 49 FOSRENOL ® 49 double blind placebo 49 anastrazole 49 Amrubicin 49 #mg BID [003] 49 metaanalysis 49 #:# randomization 49 prospective longitudinal 49 Complication rates 49 elevated CRP 49 mixed dyslipidemia 49 subanalysis 49 ABCSG 49 includes TOLAMBA TM 49 CNS systemic embolism 49 asymptomatic PAD 49 nulliparous women 49 mammographic density 49 histological subtype 49 opioid naive 49 μg L 49 AP IMPACT Credibility 49 somatostatin analog 49 abacavir lamivudine 49 pegylated interferon alpha 49 davunetide intranasal AL 49 biologic DMARD 49 mcg QD 49 Mg Uk 49 ORENCIA ® 49 ONGLYZA 49 Multicentre 49 affective psychosis 49 brivaracetam 49 Randomised 49 Electrophysiology Cardiovascular Surgery 49 serum PSA 49 brivanib 49 Hopper costarred 49 FOLOTYN ® 49 phase IIa clinical 49 Testosterone MDTS R 49 prelicensure 49 coronary revascularization procedures 49 label dose escalation 49 repeat revascularization 49 NS5B polymerase 49 INTEGRILIN R 49 MADIT CRT 49 Study Evaluating 49 Telithromycin 49 TYGACIL 49 fasting glucose 49 preclinical efficacy 49 dose cohort 49 serum folate concentrations 49 Univariate analysis 49 cediranib 49 ALB # 49 SIMPADICO 49 ancrod 49 Transgenomic Pharmacogenomics Services 49 invasive candidiasis 49 genomewide association study 49 hypertension diabetes mellitus 49 pertuzumab 49 HYVET 49 Randomized controlled 49 dyskinesia PD LID 49 MEND CABG II 49 KRAS mutations 49 Long Lesion 49 arterial thickening 49 LEXIVA 49 ongoing Phase IIIb 49 Blind Placebo Controlled 49 virologically suppressed 49 fasting insulin 49 recurrent VTE 49 IBS C 49 Relevant Triad Guaranty 49 prevalences 49 neratinib 49 BETAS 49 plus Copegus R 49 exploratory endpoints 49 safety tolerability pharmacokinetic 49 everolimus eluting stent 49 dietary questionnaires 49 aminotransferase levels 49 slow metabolizers 49 defendant Petro Krylov 49 Phase III randomized controlled 49 hypercholesterolemic patients 49 RE LY trial 49 Actress Lela Rochon 49 advanced neoplasia 49 lipid lowering medications 49 investigational protease inhibitor 49 randomized #:#:# 49 dose escalation phase 49 ritonavir boosted atazanavir 49 AIR CF2 49 elagolix 49 ALISTA 49 either acutely decompensated 49 treatment naive genotype 49 HCD# [002] 49 baseline A1C 49 Polyp Prevention Trial 49 ejection fractions 49 obese postmenopausal 49 Vytorin combines 49 lignan intake 49 genotypic resistance 49 enzastaurin 49 CTA# Injection 49 Initiates Enrollment 49 ginkgo biloba extract 49 Multicenter Phase 49 urinary BPA 49 crizotinib PF # 49 ZOLINZA 49 limiting generalizability 49 VIIBRYD 49 Screening Trial 49 evaluating satraplatin plus 49 substudy 49 patients evaluable 49 TOLAMBA 49 multicenter Phase 49 SCIg 49 Phase Ib 49 randomized Phase 2b 49 DG# compounds targeting 49 Initiated Phase 49 irinotecan cisplatin 49 #mg/dL [001] 49 multicenter phase 49 CUSTOM III 49 Multi Ethnic Study 49 SCD HeFT 49 CINQUIL 49 estrogen progestin 49 virologic failure 49 recurrent metastatic 49 chemotherapy FOLFOX 49 chlamydial infection 49 Zemplar Capsules 49 modulate ion channels 49 tumor histology 49 DMIST 49 intracerebral hemorrhages 49 Raptiva ® 49 Cloretazine 49 Saxagliptin 49 PREZISTA rtv 49 fosbretabulin 49 Aflibercept 49 CML CP 49 recurrent ischemia 49 MIRCERA 49 AZILECT R 49 RELOVAIR ™ 49 telaprevir dosed 49 ACAPODENE 49 assessing T DM1 49 atorvastatin Lipitor 49 Microplasmin 49 iPrEx 48 oral diclofenac 48 sarcoma melanoma 48 HbA 1c 48 advanced adenoma 48 NYHA functional class 48 R Everolimus Eluting 48 phase Ib clinical 48 ZYBRESTAT fosbretabulin 48 SCH # 48 sorafenib Nexavar 48 Phase III ThermoDox 48 lowest tertile 48 Pivotal Phase 48 Health Initiative Observational 48 dose pharmacokinetic 48 #mg/day [001] 48 Diovan Exforge Tekturna Zelnorm 48 serum lipids 48 A1c levels 48 RhuDex 48 better childproof containers 48 PD LID 48 Eluting Stent 48 antihypertensive therapy 48 noncardiovascular mortality 48 neurologic progression 48 Long Term Efficacy